New Delhi [India], September 28: Papadmalji Agro Foods Limited is poised for its initial public offering (IPO), with plans to raise INR 20.18 crores through the issue is a combination of a fresh issue of 25.73 lakh shares aggregating to Rs 18.52 crores and an offer for sale of 2.30 lakh shares aggregating to Rs 1.66 crores. Final press release – Papadmalj…
For its SME Initial Public Offering (IPO), Papadmalji Agro Foods Limited has established a price band of Rs 69 to Rs 72 per share. The company’s shares will open for subscription on September 29, 2026, and close on October 1, 2026. These will be listed on the NSE SME, with an estimated listing date of October 7, 2026.
Kreo Capital Pvt. Ltd. is the book-running lead manager, and MAS Services Ltd. is the registrar of the issue.
The issue proceeds will be utilized in funding the capital expenditure towards construction of building, mechanical and electrical works and procurement of plant and machinery and installation of 250 kW Rooftop Solar Power System for setting up a new manufacturing facility at Bachhasar, Bikaner, Repayment or prepayment, in full or in part, of borrowings availed by the Company from banks and general corporate purposes.
On Monday, October 5, 2026, the shares for the Papadmalji Agro Foods Limited IPO are anticipated to be allotted, and on Tuesday, October 6, 2026, the shares will be credited to the demat account of the allottees. Papadmalji Agro Foods IPO comprises a total issue size of 28,03,200 shares. The net offer of not more than 32,000 shares are allocated to QIB, not less than 7,87,000 shares are allocated to NII and not less than 18,40,000 allocated to individual investors.
Individual investors need to contribute a minimum of Rs 2,30,400 at the upper price band, considering the minimum two-lot size for an application is 3200 shares. For HNIs, the minimum bidding size is three lots, or 4800 shares, for a total investment of Rs 3,45,600 at the upper price band.
Papadmalji Agro Foods Ltd.’s revenue stood at Rs 33.53 crore and profit after tax (PAT) reported was Rs 5.21 crore for the financial year ending March 31, 2026.
Incorporated in 2017, Papadmalji Agro Foods Ltd is engaged in the processing and manufacturing of Hand-Made Papads, Machine-Made Papads, Machine-Made ready to Fry Papads, Rice Papads (Khichiya), Vrat Special Papads, and Moongodi.
The company offers services including food processing, grading, packaging, storage, and supply of agricultural and processed food products, catering to wholesalers, retailers, and institutional buyers across regional markets.
About Papadmalji Agro Foods Limited
Papadmalji Agro Foods Limited is a Bikaner, Rajasthan-based food company engaged in the in-house manufacturing of handmade papads, machine-made papads, machine-made ready-to-fry papads, rice papads (Khichiya), vrat special papads and moongodi. The Company also undertakes white-label manufacturing of handmade papads for clients, wherein products are manufactured by the Company and marketed under clients’ respective brand names and packaging.
The Company traces its origins to 2012, when Jai Agarwal founded Vishal Nankeen Bhandar in Bikaner to manufacture and sell handmade papads using traditional methods. The Papadmalji brand was registered as a device mark in 2017 and Papadmalji Agro Foods Private Limited was incorporated in December 2017. The Company converted into a public limited company in January 2025.
Papadmalji Agro Foods operates five brands — Vishal, Rozana, Papadmalji, Diamond and Zhakaas — spanning handmade and machine-made papads, rice papads, vrat special products, moongodi and ready-to-fry products. The Company combines traditional hand-rolling practices with semi-automated and automated manufacturing processes and has a network of women artisans engaged in hand-rolling papads.
The Company’s products are distributed through general trade, modern trade, quick-commerce and direct-to-consumer channels, with availability in select Middle Eastern markets through an independent merchant exporter.
Mumbai (Maharashtra) [India], September 28: Dove Soft Limited is poised for its initial public offering (IPO), with plans to raise Rs 73.26 crores through the issue, which is a combination of a fresh issue of 53.28 lakh shares aggregating to Rs 59.14 crores and an offer for sale of 12.72 lakh shares aggregating to Rs 14.12 crores. Final Dove Soft IPO_Press Relea…
For its SME Initial Public Offering (IPO), Dove Soft Limited has established a price band of Rs 104 to Rs 111 per share. The company’s shares will open for subscription on September 30, 2026 and close on October 5, 2026. These will be listed on the BSE SME, with a projected listing date of October 8, 2026.
Swastika Investmart Ltd. is the book-running lead manager and Purva Sharegistry (India) Pvt. Ltd. is the registrar of the issue. The Market Maker of the company is Swastika Investmart Ltd.
The issue proceeds will be utilized for funding working capital requirements of the Company and general corporate purposes.
On Tuesday, October 6, 2026, the shares for the Dove Soft Limited IPO are anticipated to be allotted, and on Wednesday, October 7, 2026, the shares will be credited to the demat account of the allottees. Dove Soft IPO comprises a total issue size of 66,00,000 shares. The net offer to the public is 62,70,000 shares, after excluding 3,30,000 shares allotted on a firm basis. Of the net offer, 64,800 (1.03%) are allocated to QIB, 30,70,800 (48.98%) are allocated to NII, and 31,34,400 (49.99%) are allocated to RII.
Retail investors need to contribute a minimum of Rs 2,66,400, as the minimum application size is two lots, or 2,400 shares. For NII, the minimum bidding size is three lots, or 3,600 shares, for a total investment of Rs 3,99,600 at the upper price band.
Dove Soft Ltd.’s revenue increased by 46% and profit after tax (PAT) rose by 42% between the financial years ended March 31, 2025 and March 31, 2026.
Incorporated in August 2011, Dove Soft Limited provides integrated cloud-communication solutions through SMS, RCS, Voice, WhatsApp, Email, and other digital channels. The company provides services to enterprises and OTT platforms, including SMS, WhatsApp, Voice, IVR, automated calls, E-mail, and Digital Products. The company serves clients across industries like Telecom, IT, Travel, Entertainment, Media, Advertising, Retail, Real Estate, Healthcare, BFSI, Automobile, E-commerce, and Food & Beverages, helping manage customer communication and streamline operations.
About Dove Soft Limited
Dove Soft Limited is an integrated provider of cloud communications solutions in India, commonly known as a Communications Platform as a Service (CPaaS) provider. The company offers a wide range of services across SMS, RCS, Voice, WhatsApp, Email and other digital platforms, enabling businesses to communicate efficiently with their customers through reliable and scalable messaging and engagement solutions.
With offices and operations across Mumbai, Ahmedabad, Gurugram and Dubai, Dove Soft serves enterprises as well as over-the-top (OTT) platforms, offering solutions including transactional SMS, WhatsApp messaging, voice services, automated voice call solutions, email communication and various digital products. The company also offers AI-powered capabilities across its communication solutions, including AI-enabled automation and workflow-driven customer engagement.
Dove Soft Limited was established in 2011 and has built its business around communication services, expanding its portfolio over the years across voice, email, messaging and digital communication channels. The company has also developed a unified communication platform that brings multiple channels together through a single interface, with capabilities including AI-powered automation, intelligent channel selection, real-time analytics and workflow-driven communication.
Dove Soft Limited has a presence across India and international markets and caters to enterprises and OTT platforms through its portfolio of communication solutions.
Mumbai (Maharashtra) [India], September 28: Dove Soft Limited is poised for its initial public offering (IPO), with plans to raise Rs 73.26 crores through the issue, which is a combination of a fresh issue of 53.28 lakh shares aggregating to Rs 59.14 crores and an offer for sale of 12.72 lakh shares aggregating to Rs 14.12 crores. Final Dove Soft IPO_Press Relea…
For its SME Initial Public Offering (IPO), Dove Soft Limited has established a price band of Rs 104 to Rs 111 per share. The company’s shares will open for subscription on September 30, 2026 and close on October 5, 2026. These will be listed on the BSE SME, with a projected listing date of October 8, 2026.
Swastika Investmart Ltd. is the book-running lead manager and Purva Sharegistry (India) Pvt. Ltd. is the registrar of the issue. The Market Maker of the company is Swastika Investmart Ltd.
The issue proceeds will be utilized for funding working capital requirements of the Company and general corporate purposes.
On Tuesday, October 6, 2026, the shares for the Dove Soft Limited IPO are anticipated to be allotted, and on Wednesday, October 7, 2026, the shares will be credited to the demat account of the allottees. Dove Soft IPO comprises a total issue size of 66,00,000 shares. The net offer to the public is 62,70,000 shares, after excluding 3,30,000 shares allotted on a firm basis. Of the net offer, 64,800 (1.03%) are allocated to QIB, 30,70,800 (48.98%) are allocated to NII, and 31,34,400 (49.99%) are allocated to RII.
Retail investors need to contribute a minimum of Rs 2,66,400, as the minimum application size is two lots, or 2,400 shares. For NII, the minimum bidding size is three lots, or 3,600 shares, for a total investment of Rs 3,99,600 at the upper price band.
Dove Soft Ltd.’s revenue increased by 46% and profit after tax (PAT) rose by 42% between the financial years ended March 31, 2025 and March 31, 2026.
Incorporated in August 2011, Dove Soft Limited provides integrated cloud-communication solutions through SMS, RCS, Voice, WhatsApp, Email, and other digital channels. The company provides services to enterprises and OTT platforms, including SMS, WhatsApp, Voice, IVR, automated calls, E-mail, and Digital Products. The company serves clients across industries like Telecom, IT, Travel, Entertainment, Media, Advertising, Retail, Real Estate, Healthcare, BFSI, Automobile, E-commerce, and Food & Beverages, helping manage customer communication and streamline operations.
About Dove Soft Limited
Dove Soft Limited is an integrated provider of cloud communications solutions in India, commonly known as a Communications Platform as a Service (CPaaS) provider. The company offers a wide range of services across SMS, RCS, Voice, WhatsApp, Email and other digital platforms, enabling businesses to communicate efficiently with their customers through reliable and scalable messaging and engagement solutions.
With offices and operations across Mumbai, Ahmedabad, Gurugram and Dubai, Dove Soft serves enterprises as well as over-the-top (OTT) platforms, offering solutions including transactional SMS, WhatsApp messaging, voice services, automated voice call solutions, email communication and various digital products. The company also offers AI-powered capabilities across its communication solutions, including AI-enabled automation and workflow-driven customer engagement.
Dove Soft Limited was established in 2011 and has built its business around communication services, expanding its portfolio over the years across voice, email, messaging and digital communication channels. The company has also developed a unified communication platform that brings multiple channels together through a single interface, with capabilities including AI-powered automation, intelligent channel selection, real-time analytics and workflow-driven communication.
Dove Soft Limited has a presence across India and international markets and caters to enterprises and OTT platforms through its portfolio of communication solutions.
If you object to the content of this press release, please notify us at pr.error.rectification@gmail.com. We will respond and rectify the situation within 24 hours.
Elista expands its premium television portfolio with the launch of new 55-inch and 65-inch Mini-LED PRO QLED 4K Google TVs, featuring advanced display technology, Dolby Vision, Dolby Atmos and Google TV 5.0 for an enhanced home entertainment experience.
New Delhi [India], September 28: Elista, one of India’s fast-growing consumer electronics and home appliances brands, today announced the launch of its new Mini-LED PRO QLED 4K Google TV range, available in 55-inch and 65-inch screen sizes. Designed for consumers looking to upgrade their home entertainment experience, the new televisions bring together advanced display technology, smart entertainment and a premium frameless design.
Built around the proposition “Brighter. Deeper. Smoother. More Immersive.”, the Elista Mini-LED PRO range uses Mini-LED display technology to deliver enhanced brightness, deeper contrast and richer colours. With over 500 nits brightness, the TVs are engineered to reproduce vibrant highlights and improved picture depth across movies, sports, shows and other entertainment content.
The new range supports Dolby Vision and Dolby Atmos, bringing together enhanced visual performance and immersive sound. It also features HDR10 and HLG, enabling improved contrast, colour and detail across compatible HDR content.
For viewers who enjoy fast-paced sports, action movies and gaming, MEMC (Motion Estimation, Motion Compensation) technology helps deliver smoother motion and reduces visible judder during fast-moving scenes.
At the heart of the smart experience is Google TV 5.0, which brings content from different streaming platforms together through an intuitive interface. Consumers can conveniently access popular entertainment platforms including Netflix, YouTube, Prime Video and Disney+, while Hey Google voice functionality makes it easier to search for content and navigate the TV experience.
The Mini-LED PRO TVs also feature a bezel-less design, giving the screen a clean, contemporary appearance while creating a more immersive viewing experience. Available in large 55-inch and 65-inch formats, the range is designed for consumers increasingly looking to bring a premium, cinematic viewing experience into their homes.
Commenting on the launch, Pawan Kumar, CEO, Elista, said, “The television is increasingly becoming the centre of entertainment in Indian homes, and consumers today expect a significantly better viewing experience when they upgrade to a large-screen TV. With our Mini-LED PRO range, we are bringing together advanced picture technology, immersive audio, smart functionality and premium design in one proposition. The launch is another step in our endeavour to make advanced consumer technology accessible to a wider set of Indian households.”
The launch further strengthens Elista’s growing television portfolio and reflects the brand’s focus on introducing feature-rich products tailored to the evolving expectations of Indian consumers.
The Elista 55” and 65” Mini-LED PRO Google TVs come with a 1+1 year warranty*, subject to registration and applicable terms and conditions. The 65” variant has an MRP of Rs 134999/- and 55” variant is available at an MRP of Rs 99999/-.
About Elista
Elista is a consumer electronics and home appliances brand offering a diverse portfolio across televisions, air conditioners, washing machines, refrigerators, audio products and other consumer durables. With a focus on technology, contemporary design and value, the brand continues to expand its presence across India and international markets.
If you object to the content of this press release, please notify us at pr.error.rectification@gmail.com. We will respond and rectify the situation within 24 hours.
New Delhi [India], September 28: In a landmark moment for India’s medical technology sector, Lord’s Mark Industries Limited, through its healthcare and med-tech platform, has secured registration with the Medicines & Healthcare products Regulatory Agency (MHRA), London, UK, for its haemodialysis system, marking a major step towards taking its AI-powered dialysis technology and integrated renal-care ecosystem to the UK and UK-allied markets. The company positions this milestone as India’s first and the world’s first such AI-powered dialysis ecosystem to secure the regulatory milestone at this pace, and as the first Indian company to achieve this milestone in the context of the India-UK Free Trade Agreement (FTA).
The registration covers Renalyx Health Systems Pvt. Ltd. as a manufacturer, with its haemodialysis system for institutional and home use registered under GMDN Code 58131. Lord’s Mark Industries Limited will start exporting its machine to UK and UK ally countries from early January 2027.
What began as a Made-in-India medical technology is now stepping onto the global healthcare stage. Lord’s Mark Industries is taking its world-first AI-powered integrated dialysis ecosystem beyond India, with the UK emerging as a key market in the company’s international expansion roadmap.
The development comes as the company builds on the momentum of its Renalyx AI-powered smart haemodialysis technology, which was launched as the technological backbone of an integrated renalcare ecosystem designed to bring together intelligent clinical technology, digital monitoring, operational management and continuity of care.
Unlike conventional dialysis models where the machine operates largely as an individual piece of medical equipment, the Lord’s Mark ecosystem has been conceived as a connected, intelligence-led renal-care platform. At its core is the Renalyx machine, supported by RenalOS, the company’s AI-powered clinical intelligence platform, and an integrated operational model designed to extend care beyond the dialysis session.
The ecosystem combines AI clinical intelligence, operational delivery and remote patient monitoring.
From Machine to Intelligence: Reimagining Dialysis with AI
The larger vision behind Renalyx is to move dialysis from a machine-centric model towards an intelligence-driven care ecosystem. The technology is designed to enable real-time monitoring of treatment parameters, generate predictive alerts and provide data-driven decision support during dialysis sessions.
RenalOS further enables AI-led monitoring and supports the identification of early warning signals, while connected technology can extend monitoring and continuity of care beyond the dialysis centre.
This convergence of AI, connected medical devices, cloud technology and clinical intelligence is at the heart of Lord’s Mark’s vision to create a new generation of renal-care infrastructure.
And now, that vision is preparing to cross borders.
UK: The Next Frontier
With the MHRA manufacturer and device registration, Lord’s Mark Industries is preparing to explore opportunities to deploy its dialysis technology in the UK, while also evaluating opportunities across UK-allied international markets, subject to applicable regulatory, clinical and market-access requirements.
The company’s proposed international business model extends beyond the sale of dialysis machines. Lord’s Mark plans to explore a dual pathway, supplying its Renalyx systems to healthcare providers while also establishing and operating its own dialysis centres.
This creates the potential for the company to participate across the renal-care value chain, from medical technology and AI-driven clinical intelligence to infrastructure, centre operations and patient care delivery.
India-Built. AI-Powered. Globally Positioned.
The international push represents another chapter in Lord’s Mark Industries broader healthcare strategy: building advanced medical technologies in India that can compete and create impact in global markets.
The Renalyx platform has been positioned by the company as an indigenous smart haemodialysis system developed in India, with the broader ecosystem integrating the machine with AI-powered clinical intelligence and managed dialysis operations.
Dr. Sachidanand Upadhyay, Managing Director & CEO, Lord’s Mark Industries Limited, said that:
“This is more than a regulatory milestone for us; it is a moment that validates the larger vision we have been building around Indian medical technology. We started with a simple but powerful belief that the next generation of healthcare innovation can be built in India and taken to the world. With our AI-powered dialysis ecosystem, we are not merely taking a machine into an international market; we are taking an entirely new approach to how renal care can be connected, intelligent and scalable. The MHRA registration gives us an important platform to explore the UK and UK-allied markets, where we see significant potential for both technology deployment and our own dialysis-centre operations. Our ambition is to make Renalyx a globally recognised Indian healthcare innovation and demonstrate that world-class medical technology can be conceived, engineered and scaled from India.”
Building a Global Renal-Care Ecosystem
Lord’s Mark’s international ambition is not limited to exporting equipment. The company is looking to build a scalable renal-care ecosystem that can combine technology deployment with managed healthcare delivery.
Through the proposed model, healthcare institutions could potentially access the company’s dialysis technology, while Lord’s Mark can also explore establishing its own centres to deliver technology-enabled dialysis services directly.
The company sees this integrated approach as an opportunity to create a more connected ecosystem in which the machine, AI intelligence, clinical workflows, remote monitoring and centre operations work together rather than functioning as isolated components.
For India’s med-tech sector, the development also carries a larger significance. As healthcare increasingly moves towards AI-enabled and connected systems, Indian companies are increasingly developing technologies aimed not only at domestic healthcare challenges but also at international markets.
Lord’s Mark’s UK expansion is therefore being positioned as a globalisation journey for an Indian-built healthcare technology platform, taking the company from an indigenous dialysis innovation to an international renal-care business.
The MHRA communication confirms that Renalyx Health Systems Pvt. Ltd. is registered as a manufacturer and that its haemodialysis system for institutional/home use is registered. The MHRA also expressly clarifies that this registration does not itself constitute accreditation, certification or approval by the UK Competent Authority.
For Lord’s Mark Industries, however, the registration marks the beginning of its next ambition: to take an AI-powered Indian dialysis innovation beyond borders and build a global footprint around smarter, connected and scalable renal care.
Bengaluru-based robotics company reaches a U.S. regulatory milestone in its growth across Indian and international markets
Bengaluru (Karnataka) [India], September 28-ANSCER Robotics, an Indian developer and manufacturer of autonomous mobile robots, has received Conditional Approval for its autonomous robotic platforms under the U.S. framework for foreign-produced advanced robotic devices. The milestone supports the company’s ambition to take Indian robotics engineering into global industrial markets.
The approval provides an exemption from the relevant Federal Communications Commission (FCC) Covered List restrictions for the named platforms during the approval period, subject to its terms. It addresses a national-security eligibility requirement for FCC equipment authorization, supporting ANSCER’s pathway to serving the U.S. market. It also supports supplier evaluation by businesses considering ANSCER for material-movement projects across Indian and U.S. facilities.
ANSCER’s modular AR platform supports applications including lifting, tunneling and tugging. Combined with software integration, its robots are designed to connect material movement with production and warehouse workflows, helping businesses automate repetitive transport tasks and coordinate the movement of goods.
“Our ambition is to build robotics in India that customers can choose for operations here and across the world,” said Ribin Mathew, Global CEO, ANSCER Robotics. “This milestone is a step in that journey. For Indian businesses evaluating automation, we want ANSCER to represent strong engineering, practical application knowledge and a partner that understands the demands of international operations.”
The U.S. framework reviews ownership, supply chains and manufacturing plans. ANSCER’s approval remains subject to its terms, including quarterly reporting and progress against its agreed U.S. manufacturing plan. Separate equipment-authorization and local deployment requirements continue to apply.
Indian manufacturers, warehouse operators and system integrators can connect with ANSCER to discuss their material-handling requirements and identify suitable automation applications at www.anscer.com.
About ANSCER Robotics
ANSCER Robotics develops autonomous mobile robots and software for industrial material handling. Based in Bengaluru, India, with a U.S. office in Plano, Texas, the company serves manufacturing and warehousing automation needs.
If you object to the content of this press release, please notify us at pr.error.rectification@gmail.com. We will respond and rectify the situation within 24 hours.
New Delhi [India], September 28: Elitecon International reported consolidated revenue from operations of ₹5,085.20 crore and a pre-tax profit of ₹195.98 crore for the year ended March 31, 2026, according to its audited results submitted to the BSE.
For the March quarter, consolidated revenue stood at ₹1,882.23 crore, while the company recorded a pre-tax loss of ₹73.67 crore.
Elitecon submitted a clearer copy of its standalone and consolidated results on September 26.
The results also disclosed revisions to the company’s consolidated figures for the September and December 2025 quarters. Elitecon said the earlier filings had included figures for two subsidiaries from periods before their acquisition. The error was identified during the statutory audit, it said, adding that the revisions did not affect the audited results for the year ended March 2026.
Separately, the company has outlined plans to expand its FMCG and electronics trading operations across West Asia, Africa and ASEAN markets. It is also exploring overseas manufacturing joint ventures. Elitecon said its subsidiaries in the UAE and Singapore completed a full year of operations during FY26.
Mumbai (Maharashtra) [India], September 26:Yuthika Professional has relaunched its Moroccan Argan Oil, strengthening its professional hair care range with a versatile treatment and finishing solution designed for salons, hairstylists and consumers.
The relaunched Yuthika Professional Moroccan Argan Oil is designed to support hair nourishment, conditioning, smoothness, softness and shine. With its lightweight, non-greasy formulation, the product can be incorporated at different stages of professional and regular hair care routines, including pre-styling, finishing and post-treatment care.
A Versatile Solution for Professional Hair Care
Yuthika Professional Moroccan Argan Oil has been developed as a multi-purpose hair care solution suitable for different hair types. It can be used before styling to improve manageability, as a finishing product to enhance smoothness and shine, or following salon treatments as part of a nourishing hair care routine.
The product is intended to help smooth frizz, improve softness and manageability, and give hair a polished finish without leaving it feeling excessively heavy.
The relaunch of Yuthika Professional Moroccan Argan Oil reflects our continued focus on providing salon professionals and consumers with effective and versatile hair care solutions. Moroccan Argan Oil has been an important part of our hair treatment range, and through this relaunch, we aim to bring renewed attention to its multiple applications across styling, finishing and post-treatment hair care.
Designed for Salon and At-Home Hair Care
Professional hair services increasingly involve a combination of coloring, conditioning, treatment and styling, creating a need for products that can complement different stages of the salon process.
Yuthika Professional Moroccan Argan Oil can be incorporated into salon services where nourishment, conditioning, smoothness and manageability are required. Hairstylists can adjust the quantity and application depending on the client’s hair texture, length, condition and styling requirements.
The product can also be incorporated into regular at-home hair maintenance, offering consumers a professional-oriented treatment option between salon visits.
Supporting Post-Treatment Hair Maintenance
Frequent styling, hair coloring and other salon processes can influence the way hair looks and feels, making appropriate aftercare an important part of a hair maintenance routine.
Yuthika Professional Moroccan Argan Oil can be used following hair treatments as a nourishing and finishing step. Its multi-purpose format allows it to complement the brand’s professional hair color, hair care, treatment and styling categories.
The product is available in 30 ml and 100 ml pack sizes, giving both professional users and consumer’s options based on their individual usage requirements.
Strengthening Yuthika Professional’s Hair Care Range
The relaunch forms part of Yuthika Professional’s continued focus on strengthening its professional hair care offering.
The brand’s product range spans professional hair color, hair care, hair treatment and styling, including shampoos, hair masks, oil treatments, serums, conditioners, heat protection and other specialized hair care solutions.
With the relaunch of Moroccan Argan Oil, Yuthika Professional is reinforcing its treatment and finishing product range with a versatile oil-based solution that can be used across professional salon services as well as regular hair maintenance routines.
About Yuthika Professional
Yuthika Professional is a professional beauty and hair care brand offering products across hair color, hair care, hair treatment and styling categories. The brand provides a range of professional-oriented solutions developed for salon professionals, hairstylists and regular hair maintenance.
If you object to the content of this press release, please notify us at pr.error.rectification@gmail.com. We will respond and rectify the situation within 24 hours.
New Delhi [India], September 26: AutoSoft Training and Solutions, a Pune-based technical training institute, has announced the launch of a new set of advanced learning programs covering Computer-Aided Design (CAD), Automotive Product Design, and Embedded Systems. The expanded curriculum is aimed at equipping engineering graduates and working professionals with practical, industry-relevant skills across some of the fastest-growing domains in manufacturing and mobility.
The new programs bring together core areas of contemporary product engineering — from CAD and CAE fundamentals to specialized automotive design disciplines and embedded systems development, including AUTOSAR-based training. The curriculum has been structured to give learners hands-on exposure to tools and workflows currently used across the automotive, manufacturing, and technology sectors, bridging the gap between academic learning and industry application.
CAD training under the new offering focuses on building strong design fundamentals, covering modeling, drafting, and design validation techniques that form the backbone of product development across industries. The Automotive Product Design track goes a step further, addressing specialized areas such as component design and the plastic domain, giving learners insight into the processes automotive manufacturers rely on to take a product from concept to production.
On the electronics side, the Embedded Systems program addresses a segment of engineering that continues to see strong demand as vehicles and industrial systems grow increasingly software-driven. The curriculum is designed to introduce learners to embedded systems architecture, development practices, and AUTOSAR concepts relevant to the automotive electronics landscape.
“Our goal is to bridge the gap between academic learning and industry requirements by providing practical, job-oriented training in emerging CAD, automotive design, and embedded technologies.”
Krishnaray Gosalwad Savithri Gosalwad
— Founder / Training Head, AutoSoft Training and Solutions
AutoSoft Training and Solutions has built its reputation on structured, practice-oriented training delivered by experienced faculty, with a continued focus on helping learners translate classroom knowledge into workplace-ready skills. The institute’s programs are designed for both fresh engineering graduates seeking to strengthen their employability and working professionals looking to upskill in specialized technical domains.
With this expansion, AutoSoft Training and Solutions reinforces its position as a technical training provider in Pune catering to the evolving needs of the CAD, automotive design, and embedded systems ecosystem.
If you object to the content of this press release, please notify us at pr.error.rectification@gmail.com. We will respond and rectify the situation within 24 hours.
Ahmedabad (Gujarat) [India], September 26: In an increasingly interconnected global pharmaceutical industry, accurate technical communication has become essential for regulatory inspections, GMP audits, international business, and market expansion. Mr. Ashish Udani, an experienced Spanish Interpreter and Translator based in India, has developed a specialized professional practice supporting pharmaceutical, biotechnology, healthcare, medical device, and blood plasma-derived product companies working with Spanish-speaking markets.
With extensive experience in pharmaceutical terminology, GMP requirements, regulatory inspections, manufacturing processes, quality systems, technical documentation, and Latin American regulatory environments, Mr. Udani provides specialized Spanish interpretation and translation support to Indian manufacturers, international auditors, regulatory professionals, and pharmaceutical companies.
His experience extends beyond conventional pharmaceutical manufacturing and includes biotechnology plants and facilities involved in blood plasma-derived products, where technical accuracy and clear communication are particularly important during regulatory inspections and quality discussions.
Specialized Spanish Interpreter for Pharmaceutical and Biotechnology Audits
Pharmaceutical and biotechnology audits require much more than general language interpretation. They involve complex technical terminology, manufacturing processes, quality systems, validation, qualification, documentation, regulatory requirements, and inspection procedures.
Mr. Ashish Udani provides professional Spanish interpretation for:
GMP and regulatory inspections
COFEPRIS and DIGEMID audits
Pharmaceutical manufacturing plant inspections
Biotechnology plant inspections
Blood plasma-derived product manufacturing audits
API and formulation plant audits
Quality assurance and quality control discussions
Validation and qualification discussions
Technical meetings and plant visits
Supplier and customer audits
Documentation reviews
Virtual and on-site inspections
Business meetings with Spanish-speaking pharmaceutical companies
His role is to facilitate clear and technically accurate communication between Indian manufacturing teams and Spanish-speaking auditors, inspectors, regulatory professionals, customers, and business partners.
Experience Supporting COFEPRIS and DIGEMID Audits
Mr. Udani has developed extensive experience supporting audits involving Latin American pharmaceutical regulatory authorities, particularly COFEPRIS (Mexico) and DIGEMID (Peru).
He has participated in 100+ COFEPRIS-related audits and regulatory inspection assignments, covering pharmaceutical and biotechnology manufacturing environments, including facilities associated with blood plasma-derived products and other high-risk pharmaceutical manufacturing operations.
His audit experience includes discussions involving areas such as:
Good Manufacturing Practices (GMP)
Quality Management Systems
Validation and qualification
Validated State
Annual Product Quality Review (APQR)
Risk analysis and risk management
Manufacturing processes
Quality Control and Quality Assurance
Supplier qualification
Technical documentation
Regulatory compliance
ICH and WHO-related requirements
API and finished pharmaceutical products
Biotechnology manufacturing processes
Blood plasma-derived products
Through his specialized interpretation support, Mr. Udani helps Indian pharmaceutical and biotechnology companies communicate technical information accurately during inspections conducted by Spanish-speaking regulatory authorities and international auditors.
Specialized Experience in Biotechnology and Blood Plasma-Derived Products
One of the distinctive areas of Mr. Udani’s professional experience is his exposure to biotechnology manufacturing facilities and blood plasma-derived products.
Manufacturing and regulatory discussions in this sector can involve highly specialized terminology relating to raw materials, plasma-derived products, manufacturing controls, quality systems, validation, testing, traceability, documentation, and regulatory compliance.
His experience interpreting technical discussions in these environments enables him to support communication between Indian biotechnology and pharmaceutical manufacturers and Spanish-speaking regulatory professionals.
This specialized exposure is particularly relevant for companies involved in international inspections, regulatory registrations, supplier qualification, technical discussions, and Latin American market expansion.
Technical Spanish Translation for Pharmaceutical and Biotechnology Documentation
In addition to real-time interpretation, Mr. Ashish Udani provides Spanish translation services for technical, pharmaceutical, biotechnology, regulatory, and quality-related documentation.
His translation services may include:
Site Master Files
Validation Master Plans
Standard Operating Procedures (SOPs)
Quality Manuals
Product Dossiers
Regulatory Submissions
Audit Reports
Technical Reports
Manufacturing Documents
Quality Control Documents
Quality Assurance Documents
Validation and Qualification Documents
Risk Assessment Documents
Pharmaceutical and biotechnology technical documentation
The focus is on maintaining technical accuracy, terminology consistency, document integrity, and professional presentation in Spanish.
Supporting International Pharmaceutical Inspections
During an international regulatory inspection, communication must be precise. Questions from auditors can involve highly technical subjects, and responses may require immediate interpretation between Spanish and English.
Mr. Udani provides real-time interpretation during:
His specialized understanding of pharmaceutical terminology allows him to interpret technical discussions in context rather than relying solely on general-language translation.
Connecting Indian Pharmaceutical Companies with Latin American Markets
India is one of the world’s major pharmaceutical manufacturing and export hubs, while Latin America represents an important international market for Indian pharmaceutical manufacturers.
Mr. Udani supports Indian companies communicating with Spanish-speaking markets in Mexico, Peru, Spain, and other Spanish-speaking countries, providing language support for regulatory inspections, customer meetings, supplier audits, technical discussions, and international business development.
His services help companies communicate more effectively with Spanish-speaking customers, auditors, regulatory professionals, distributors, and business partners.
Industries and Sectors Served
Mr. Udani’s professional experience includes language and technical communication support across several sectors, with particular specialization in:
Pharmaceutical Manufacturing
Biotechnology
Blood Plasma-Derived Products
API Manufacturing
Finished Pharmaceutical Products
Medical Devices
Healthcare
Chemicals
Ceramics
Textiles
Brass Components
Industrial Manufacturing
His experience across these technical sectors enables him to adapt his interpretation and translation services to specialized business and regulatory environments.
Why Pharmaceutical and Biotechnology Companies Work with Mr. Ashish Udani
Mr. Udani combines professional Spanish language expertise with practical exposure to pharmaceutical manufacturing and regulatory audit environments.
His key areas of specialization include:
100+ COFEPRIS-related audit assignments
Experience supporting DIGEMID audits
Pharmaceutical GMP audit interpretation
Biotechnology plant interpretation
Blood plasma-derived product audit exposure
Specialized pharmaceutical terminology
Regulatory and technical document translation
Real-time Spanish interpretation during inspections
Virtual and on-site interpretation
Technical meetings and plant visits
Communication between Indian manufacturers and Spanish-speaking regulatory professionals
Latin American pharmaceutical market support
A Specialized Language Partner for International Regulatory Communication
In pharmaceutical and biotechnology manufacturing, language is closely connected with technical accuracy and regulatory communication. A misunderstanding during an inspection can affect how technical information is presented, discussed, or documented.
Mr. Ashish Udani provides specialized Spanish interpretation and translation support designed specifically for these demanding environments.
With experience across pharmaceutical manufacturing, biotechnology, blood plasma-derived products, medical devices, and regulatory audits, he continues to support Indian companies working with Spanish-speaking regulatory authorities, pharmaceutical companies, customers, and business partners.
His work represents a specialized combination of Spanish language expertise, pharmaceutical terminology, regulatory audit exposure, and international business communication, helping Indian companies strengthen their communication with Spanish-speaking markets.
Contact Information
Ashish Udani
ISO 9001:2015 Certified Translator
Spanish Interpreter | Pharmaceutical & Biotechnology Audit Specialist | LATAM Business Development Consultant
Real-time Spanish interpretation for pharmaceutical and biotechnology audits, GMP inspections, regulatory meetings, conferences, technical meetings, plant visits, and virtual inspections.
Specialized regulatory support: COFEPRIS (Mexico) and DIGEMID (Peru), including pharmaceutical, biotechnology, and blood plasma-derived product manufacturing environments.
If you object to the content of this press release, please notify us at pr.error.rectification@gmail.com. We will respond and rectify the situation within 24 hours.
